Smiths Detection, the global threat detection and security technology company, announces that its BioFlash Biological Identifier has been successfully deployed in real-world environments to detect airborne COVID-19 in almost real-time.

BioFlash works by collecting and analysing air samples using sensitive, selective and rapid detection technology to identify the presence of dangerous pathogens onsite without the need to involve a laboratory.

• In February, Smiths Detection announced test results from a study with the US Army, which verified that BioFlash could identify SARS-CoV-2 in a laboratory setting.
• Today, the Company is confirming that the BioFlash has been used by the University of Maryland, Baltimore County (UMBC) to identify airborne SARS-CoV-2 inside their campus and prevent the spread of the virus.
• The University of Oregon has also successfully tested the device in quarantine and isolation spaces for students who tested positive for SARS-CoV-2, further verifying the capabilities of the BioFlash in a real-world setting.

This technology can be used to inform COVID-19 mitigation strategies and provide confidence for commercial premises to reopen and stay open, especially buildings such as medical centers and schools where there is a high risk of COVID-19 exposure.

FLIR Systems, Inc. announced it has won a contract with the Defense Advanced Research Projects Agency (DARPA) to rapidly develop novel fabrics with embedded catalysts and chemistries that can fight and reduce chemical and biological threats upon contact. The revolutionary fabrics will be incorporated into protective suits and other equipment such as boots, gloves, and eye protection that can be worn by troops on the battlefield, medical experts, healthcare workers, and more. FLIR received $11.2 million in initial funding for the potential five-year effort worth up to $20.5 million, including options.

The goal of DARPA’s Personalized Protective Biosystems (PPB) program is to reduce the substantial weight and physiological burden of current Personal Protective Equipment (PPE) so soldiers and other specialists can better perform their tasks. PPB will combine novel, lightweight protective materials with new prophylactic medical technologies that mitigate chemical and biological threats at vulnerable tissue barriers, notably the eyes, skin and lungs. The complete system will enable troops and first responders to operate without the burden of carrying and wearing PPE, which can cause heat stress and reduce time spent completing the mission.

“With lives at stake, future operators wearing PPB suits will gain a major edge in staying protected from toxic chemicals and emerging biological threats such as dangerous viruses,” said Mark Stock, VP and general manager of the Sensor Systems business at FLIR. “We’re honored DARPA has chosen us to lead this extraordinary and highly innovative effort to develop first-of-its-kind protective fabrics for our nation’s warfighters, health and public safety officials.”

FLIR and its teaming partners will develop a prototype fabric material, the Integrated Soldier Protective System (ISPS), for testing by government laboratories. Work will be performed at FLIR facilities in Pittsburgh. The ISPS award consists of a two-year base period, two-year first option, and one-year final option. The result after five years will be a suite of prototype protective fabrics and garments ready for transition to a program of record with the U.S. Department of Defense.

FLIR safeguards people and property by providing tools that see and sense harmful Chemical, Biological, Radiological, Nuclear, and Explosives (CBRNE) substances. For more on FLIR Systems’ threat detection products, visit www.flir.com/threat-detection/.

Originally published in Council on Strategic Risks by By Andrew Weber and Yong-Bee Lim

Operation Warp Speed – the program of major U.S. government investments that drove the rapid development of multiple vaccines for the COVID-19 virus – teaches us a lesson about how to fund the fight against biological threats in the future. That lesson is about establishing a vision of significant, sustained and stable government funding to drive focused and rapid private sector-developed solutions. We propose $10 billion per year for the Department of Defense, and $10 billion per year for Health and Human Services, over 10 years, for biodefense-related programs and initiatives. Or 10 + 10 Over 10.

COVID the Harbinger – The Rising Tide of Biological Threats

As we pass the one-year anniversary of when the World Health Organization declared the COVID-19 outbreak a pandemic, we are approaching 122 million cases and almost 3 million deaths world-wide. These numbers are a grim reminder of the losses we have experienced and a testament to how poorly this pandemic was handled around the globe. 

Unfortunately, accelerated global outbreaks are just one type of biological threat that is potentially on the rise. Some experts note that the explosion of work on pathogens with pandemic and weaponization potential has increased the probability of lab accidents and geopolitical miscalculations as more actors engage in activities that teeter at the edge of biodefense and bioweapons. Further, rapid advances in the life sciences capabilities are making them easier to use and capable of doing more, complex things. These factors, along with the convergence of biology with fields like engineering, artificial intelligence, quantum computing, and additive manufacturing (i.e. 3D printing) are also increasing the capabilities of state and non-state actors. These dynamics are also creating complex, unpredictable outcomes that make predicting technology trajectories exceptionally difficult. The technological state of play thus exacerbates concerns that biological weapons may become cheaper to produce, easier to deploy, and accomplish the desired outcome with greater precision than ever before.

The Ghosts of Biodefense Funding Past – Addressing Funding Stability and Budget Cuts

The Biden Administration has communicated its commitment to addressing and responding to natural, accidental and deliberate biological threats as a top national security priority. In National Security Memorandum 1, the Administration committed to “treat epidemic and pandemic preparedness, health security, and global health as top national security priorities…to create a world that is safe and secure from biological threats.” Executive Order 13994 directed departments and agencies to address COVID-19 and future biothreats by leveraging “the best available science and data, including by building back a better public health infrastructure.” The Interim National Security Strategic Guidance emphasized  addressing “pandemics and other biological risks [which]…pose profound and, in some cases, existential dangers.”

To properly resource the Administration’s commitment to prioritizing biological threats, there are two historic funding trends it will need to address. The first is unstable funding to important biodefense programs and initiatives. A National Research Council report found that unstable and unpredictable funding negatively impacted Department of Defense (DoD) programs like the Defense-Wide Chemical and Biological Defense Program (CBDP), which supports the US Armed Forces by researching and developing capabilities to “win decisively in chemical, biological, radiological, and nuclear environments,” compromising its ability to to achieve its important mission. This phenomenon is not limited to DoD. A Congressional Research Service report noted that the Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response’s (HHS/ASPR) Strategic National Stockpile (SNS) also experienced unstable budgets from start to present. 

The second issue is the tendency for biodefense funding to be cut at critical times or to make room for other defense priorities. During the COVID-19 pandemic, one of the deadliest and most significant biological events in modern times, the DoD sought to spend less on chemical and biological defense-related programs. It sought to achieve this through a nearly 15%  drop in research and procurement funding for CBDP – the very program that is meant to help maintain force readiness despite adverse chemical, biological, radiological, and nuclear combat conditions. This cut was justified by former Defense Secretary Esper to purchase hypersonic missiles and other weapons needed to deter or fight Russia and China. The SNS also experienced such cuts during the Obama Administration, resulting in hard decisions for what to stockpile, what items to reduce, and what items to let expire due to heated battles in Congress concerning the rising federal budget and the debt ceiling.

10B + 10B Over 10 – A Funding Vision for U.S. Biodefense

The convergence of increasing biological risks with the willingness of the U.S. government to meet the difficult challenges of these threats head-on provides us with a unique opportunity – an opportunity to properly and stably fund U.S. biodefense programs and initiatives. Biodefense initiatives and programs exist across many government agencies, including the Department of Energy, Department of State, Department of Homeland Security, U.S. Department of Agriculture, Department of Health and Human Services, and Department of Defense. In a recent piece in Arms Control Today, Andy Weber proposed a funding model that focused on HHS and DoD to provide a vision that takes significant strides for addressing biothreats through the purview of these two government agencies. This model, called “10 + 10 Over 10”, includes:

• $10 billion per year to HHS for biodefense-related programs and initiatives: This level of funding would help support multiple efforts, including but not be limited to: 1) enhancing the ability of the Biomedical Advanced Research and Development Authority (BARDA) to transition medical countermeasures from research through advanced development; 2) supporting efforts to modernize and enhance HHS/ASPR’s SNS initiative, and; 3) helping build the necessary capacity and expertise to enhance FDA’s capabilities for reviewing and ensuring that medical countermeasures are safe and effective.
• $10 billion per year to DoD for biodefense-related programs and initiatives: This level of funding would also help support multiple efforts, including but not be limited to: 1) providing stable and necessary funding to restore and enhance CBDP’s budget, particularly its medical  component, to increase capabilities to research, develop, and leverage emerging and next-gen technologies for early warning systems, rapid characterization of microbes, rapid-response platforms to develop medical countermeasures; 2) supporting and expanding global efforts to strengthen relationships and reduce biological dangers through the Department’s Biological Threat Reduction Program (BTRP); 3) enhancing the care and meeting the health and wellness needs of our service-members through the infectious disease components of the Defense Health Program; and 4) encouraging and innovating breakthrough technologies for national security through the Defense Advanced Research Projects Agency (DARPA).
• Maintaining this $10B annual level of funding both for HHS and DoD for 10 years.

Further, this funding approach is also meant to foster a vision of collaboration – one where partnerships between DoD, HHS, and the private sector are the norm. This vision is inspired by the efforts and achievements of Operation Warp Speed (OWS): the moon-shot initiative of public and private stakeholders that took the world from sequence to vaccine in less than a year. 

HHS and DoD have complementary capabilities that, together, can make great strides towards the capabilities needed for deterring bio attacks and preventing pandemics. For example, defense programs to counter biological threats house special authorities and skilled acquisition personnel that were leveraged in partnership with HHS to accelerate treatments and vaccines for COVID-19. Both departments need to be fully resourced on a strong and consistent basis going forward, in addition to each department’s leaders ensuring that collaboration continues.

Operation Warp Speed showed that when governments offer sufficient funding and expertise, the private sector can swiftly bring incredible advancements in sequencing technologies, synthetic biology, and other innovative technologies to the table, and the U.S. and the globe can overcome even seemingly insurmountable challenges. This is the type of bold funding and collaborative vision necessary to not only overcome the rise of biological threats, but enable all of humanity to thrive in the 21st century.

908 Devices, a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the U.S. Border Patrol selected the MX908® – a handheld, battery-powered, mass spectrometry device – to standardize its trace drug detection at 20 field locations across the U.S. borders, from North to South and in the Caribbean. The U.S. Border Patrol purchased more than 60 MX908 units, which are designed for rapid analysis of vapor, liquid and solid materials of unknown identity, to prevent drug smuggling and to work with local and state law enforcement in support of its counter drug mission. 

The opioid crisis is, unfortunately, worsening.  Drug overdose deaths are on the rise, and the CDC estimates that the U.S. suffered an almost 17% increase in drug-related deaths from May 2019 to May 2020, in part, accelerated by the pandemic. This frightening trend further drives the urgency for the point-of-need analysis that our MX908 provides.

“We’re proud to support U.S. Border Patrol as they field our MX908 devices across their enterprise to provide their first responders with the ability to better serve and protect our borders and country,” said John Kenneweg, Vice President of Government at 908 Devices. “We’ve seen a rise in the creation and distribution of synthetic opioids in particular because not many technologies can identify drugs at these trace levels. Even as bad actors try to trick the system by slightly tweaking analogs, the MX908 helps U.S. agencies like Border Patrol future proof their mode of drug identification, so that the technology they get trained on today can evolve with them in support of their counter drug mission in the years ahead.”

908 Devices’ MX908 is utilized by a wide spectrum of users for a variety of forensic field applications such as chemical, explosive, priority drug and HazMat operations, detecting materials at the trace level. The agile, multi-purpose device empowers front line workers, military personnel, and public safety officers with real-time intelligence in seconds. Elite responders rely on our handheld devices to combat the opioid crisis, detect counterfeit pharmaceuticals and illicit materials in the air or on surfaces at levels 1,000 times below their lethal dose. The MX908 is the only technology of its kind that can detect more than 2000 fentanyl analogs, which is critical as Fentanyl and its many analogs are largely driving the opioid epidemic.”

Viken Detection, pioneer of x-ray imaging and analytical devices, today announced that it has appointed Dr. Hanh Lai to lead its newly formed Chemical Detection and Environmental Hazards business unit.

Prior to joining Viken, Dr. Lai held various technical leadership roles at Rapiscan and Safran (formerly Morpho Detection) in their Explosive Trace Detection divisions. She received her doctorate in Forensic Chemistry at Florida International University and a Bachelor of Science degree in Chemical Engineering at the University of Toronto. Dr. Lai is named inventor/co-inventor on 18 U.S. patents and patent applications.

“Hanh is not only an accomplished technologist, but also a natural leader with superb business instincts,” stated Jim Ryan, CEO of Viken Detection. “I am thrilled to work with her as we introduce exciting new product platforms this quarter and continue to provide our customers with unique solutions.”

“My passion has always been to develop new technology that helps keep people safe,” said Dr. Lai. “At Viken Detection I get to do that every day, working with a group of talented engineers to accomplish that mission.”

For more information about Viken Detection, please visit us at www.vikendetection.com.

The CONVERGE facility, headquartered at the Natural Hazards Center at the University of Colorado Boulder, is so pleased to announce the release of a seventh CONVERGE Training Module. This online course, which was supported by the Centers for Disease Control and Prevention and the National Science Foundation, focuses on Broader Ethical Considerations for Hazards and Disaster Researchers. You can register and access the free module here:https://converge.colorado.edu/training-modules.

To learn more, please join us Thursday, April 15, 2021, from 10:00-10:30 a.m. Mountain Time for a live webinar where our team will provide a demonstration of the CONVERGE Broader Ethical Considerations for Hazards and Disaster Researchers Training Module. To register for the upcoming webinar, please visit: https://converge.colorado.edu/communications/webinar-series/broader-ethical-considerations-training-module. 

This new module is part of a larger series designed to accelerate the education of a diverse hazards and disaster workforce. The new module focuses on the ethical challenges that arise throughout the research process and provides recommendations for facilitating ethical decision-making and action in disaster research. This module, like the others in the series, concludes with a 10-question quiz. Upon successful completion of the quiz, users receive a certificate, which is worth one contact hour of general management training through the International Association of Emergency Managers (IAEM) certification program. These modules can be useful for classroom assignments as well as other activities. Please see the CONVERGE Assignment Bank for sample activities: https://converge.colorado.edu/resources/training-modules/assignment-bank. 

You can sign up for additional free resources and updates at the CONVERGE website at: https://converge.colorado.edu/signup

Oringinally published by Poynter

 The first big question the public will ask is whether any of the 15 million doses of Johnson & Johnson’s vaccine that workers ruined in a manufacturing mistake made it to vaccination lines. The New York Times, which broke this story late Wednesday, says that the mistake does not involve any of the vaccines in the supply chain right now. In other words, the mistake was contained at the factory. 

That should be a loud and clear message today; that the safety of vaccines that people are lined up to get is not in question.

All of the doses in the pipeline right now came from Johnson & Johnson’s plant in The Netherlands. The mistake happened at the plant of a subcontractor, Emergent BioSolutions, which is in Baltimore. 

Johnson & Johnson hired Emergent BioSolutions to manufacture the active ingredient. Workers at the facility mistakenly mixed ingredients for the Johnson & Johnson vaccine with those of another manufacturer’s shot. Emergent does contract work for both Johnson & Johnson and Moderna.

The Baltimore Sun says the mixup happened a couple of weeks ago, but until now, word did not leak. Johnson & Johnson issued a statement Wednesday night that doesn’t mention the mistake until the third paragraph. When it does get to the issue, it says:

As with the manufacturing of any complex biologic medication or vaccine, the start-up for a new process includes test runs and quality checks to ensure manufacturing is validated and the end product meets our high-quality standards. This approach includes having dedicated specialists on the ground at the companies that are part of our global manufacturing network to support safety and quality.

This quality control process identified one batch of drug substance that did not meet quality standards at Emergent Biosolutions, a site not yet authorized to manufacture drug substance for our COVID-19 vaccine. This batch was never advanced to the filling and finishing stages of our manufacturing process.

This is an example of the rigorous quality control applied to each batch of drug substance. The issue was identified and addressed with Emergent and shared with the United States Food & Drug Administration (FDA).

Politico explains the backstory:

Emergent was supposed to send its drug substance to Catalent, a New Jersey drug manufacturer, to bottle the vaccine. The FDA approved Catalent’s production role last week, and Emergent had already begun shipping millions of doses to the other firm, people familiar with J&J’s authorization told POLITICO last week. But Catalent cannot release the Emergent doses without the Maryland company’s emergency clearance.

The Johnson & Johnson vaccine is the only one-dose shot approved for use in the United States. Even though this supply interruption is not insignificant, Pfizer and Moderna’s two-shot vaccines are in full production (and Pfizer is even ahead of its production schedule), so it is uncertain right now if any Americans will have their vaccinations delayed. Johnson & Johnson says it expects to meet its goal of producing a billion doses by the end of 2021.

The larger unanswerable question is how will this bad news sit with the already skeptical unvaccinated public? 

The U.S. Department of Labor’s Occupational Safety and Health Administration (OSHA) today issued a proposed rule to update the agency’s Hazard Communication Standard (HCS) to align with the seventh revision of the Globally Harmonized System of Classification and Labelling of Chemicals (GHS).

OSHA expects the HCS update will increase worker protections, and reduce the incidence of chemical-related occupational illnesses and injuries by further improving the information on the labels and Safety Data Sheets for hazardous chemicals. Proposed modifications will also address issues since implementation of the 2012 standard, and improve alignment with other federal agencies and Canada.

Individuals may submit comments identified by Docket No. OSHA-2019-0001, electronically at http://www.regulations.gov, which is the Federal e-Rulemaking Portal. Read the Federal Register notice for details. The deadline for submitting comments is April 19, 2021.

OSHA has preliminarily determined that the proposed modifications would enhance the effectiveness of the standard by improving dissemination of hazard information so employees are more appropriately apprised of exposure to chemical hazards in the workplace. 

Established in 1983, the Hazard Communication Standard provides a standardized approach to workplace hazard communications associated with exposure to hazardous chemicals. OSHA updated the standard in 2012 to align with the third revision of the United Nations’ GHS to provide a common and coherent approach to classifying chemicals and communicating hazard information.

908 Devices Inc. a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the receipt of a multi-year $25M purchase order from the U.S. Army Program Manager for Close Combat Systems. The company will supply more than 350 additional MX908® trace-level detection devices to the U.S. Army’s Explosive Ordnance Disposal (EOD) Render Safe Sets, Kits & Outfits (RS SKO) program over the next two years. 
 
“The MX908 will provide the U.S. Army the ability to detect and identify a range of chemical threat materials quickly and safely at the point of need,” said John Kenneweg, Vice President of Government at 908 Devices. “We are excited that our high-pressure mass spectrometry™ (HPMS) technology was selected by the Department of Defense for this large enterprise program and look forward to enabling their users to safety accomplish their missions.” 

Utilized by responders conducting response operations around the world, the MX908’s high sensitivity and selectivity delivers real-time actionable intelligence in seconds. The MX908 is one of ten different capabilities provided in this new program, and will enable detection and identification of priority drugs, chemical agents, and trace explosives with the company’s proprietary HPMS device. 908 Devices will support the program through 2025 as part of the contractual commitments. 

The German company tasked with clearing hazardous material at Beirut port, and around the country, has discovered radioactive material at the Zahrani Oil Installation, which is about 50km south of the port. 

According to Prime Minister Diab the substance found "is a highly pure nuclear substance" and posed a danger. The head of the installation Ziad el-Zein, told local Al-Jadeed TV that Combi Lift inspected the facility and found eight small containers that weigh less that 2 kilograms (4.4 pounds) containing depleted uranium salts. El-Zein added that the material has been stored at the facility since the 1950s, when it was run by the Mediterranean Refinery Company which was active in Lebanon until the late 1980s.

A document from the Zahrani Oil Installation that was posted by local media Friday said that the committee following up on the "chemical material" decided to move it to the laboratories of the Lebanese Atomic Energy Commission. The March 22 document warned that the Lebanese atomic commission will inform the International Atomic Energy Agency that it cannot store the material in Lebanon in accordance with international standards.

Today, Drone Major Group has announced the launch of the first ever drone technology ‘Test and Development Area’ project, to be created in the Liverpool City Region. The project is to be delivered in partnership with Liverpool City Region Combined Authority (LCRCA) and is expected to put the region on the path to become a global leader in the deployment of cutting-edge drone technology.   

This pioneering initiative, entitled Phoenix I, is the first in a series of interconnected projects developed by Drone Major Group, with several regional partners, to deliver, for the first time, commercially viable, scalable and environmentally sustainable drone services across all environments (surface, underwater, air & space), and in all the sectors that are vital for the UK and world economy. The transformational project promises numerous benefits to the City Region, creating new investment and economic growth, employment, skills, education and a cleaner environment. 

LCRCA has played an instrumental convening role working with Drone Major Group to facilitate the active involvement of many of the region’s most vital 
stakeholders in the delivery of the project, including, Peel Ports Group, LogisticsUK, SP Energy Networks, Manufacturing Technology Centre (MTC) 
Liverpool John Lennon Airport, the University of Liverpool and Liverpool John Moores University.  

A roadmap has been created for this unique project which identifies key themes, outlining a clear pathway to develop operational drone capabilities to be delivered in the fields of urban logistics, the environment, security, maritime logistics, port & maritime, and the wider community. All projects within the newly established Phoenix programme, which currently comprises 10 new initiatives addressing these sectors across the UK, will share a common operational model and advanced data analysis to ensure that progress accelerates exponentially.  

This commercially accelerating approach is set to stimulate Liverpool City Region’s inward investment opportunities, while enhancing the region's global recognition as a hub for cutting-edge technological innovation. This is a particularly pivotal time for the City Region, with the Combined Authority’s emerging Climate Action Plan crystallising its decarbonisation agenda, together with the grant of Freeport status for Liverpool City Region announced by the Chancellor in his budget speech on 3 March 2021.  

The Liverpool City Region benefits from some of the country’s most outstanding digital infrastructure, academic knowledge and individual experts who will be integral to realising the potential of autonomous drone systems in the UK, such as the University of Liverpool’s Centre for Autonomous Systems Technology (CAST), Liverpool Institute for Sustainable Coasts and Oceans (LISCO) and Virtual Engineering Centre (VEC), and the drone research group at Liverpool John Moores University.  

Robert Garbett, Founder of Drone Major Group commented: “Drones represent an unprecedented growth opportunity across a huge number of global industries. Liverpool City Region has clearly demonstrated its commendable intent to adopt a sustainable and commercially viable drone technology system for the City, ahead of the curve, which sets an example to all.  

“The potential for this unique collaborative initiative is vast. It enables cities, regions and industries to achieve their potential and will create an overwhelmingly positive impact on UK, and indeed world economic growth through enhanced commerce, employment, skills, education and decarbonisation.” 

Metro Mayor, Steve Rotheram of the Liverpool City Region added: “The Liverpool City Region is a digital powerhouse. We have the world class infrastructure, expertise and ambition to be leaders of the Fourth Industrial Revolution. It’s fantastic to see the Drone Major Group recognising that by choosing to open their test and development area here. 

“This project will deliver new jobs and investment and will attract people to our area not just to work but to study too, knowing that we are working on cutting edge and exciting projects such as this, as well as ambitious plans in everything from digital infrastructure and tidal power.” 

In recent years, the production and distribution of lethal narcotics such as heroin, fentanyl, MDMA and others have become increasingly sophisticated. This has caused new challenges for law enforcement officers, who are often the first to come in contact with these substances and need to identify narcotics and make informed decisions at the site.

The new Thermo Scientific 1064Defender Raman Analyzer is directly addressing this challenge. The new analyzer features a touchless, targeted methodology that enhances identification of street heroin and other fluorescent narcotics, without removing them from their packaging. The analyzer’s scanner mode, which features a comprehensive, modular, and user-added library of controlled substances, takes the guesswork out of identifying substances. It delivers results in a clear warning or alert format, ensuring users know the best next steps. The scanner, combined with the analyzer’s GPS and a digital camera, enables an improved path to interdiction and solid chain of custody. The 1064Defender Raman Analyzer has Wi-Fi and USB connectivity, allowing for seamless data flow throughout the law enforcement agency.

“Potential exposure to a harmful, illicit narcotic is a high-stress situation for law enforcement officials and presents an urgent need to identify the substance in order to take proper action,” says Chloe Hansen-Toone, vice president and general manager of Thermo Fisher Scientific's field and safety instruments business. “The 1064Defender Raman Analyzer was developed with this specific situation in mind. Its scanner technology allows for quick decision-making without compromising safety. The 1064 Defender enables law enforcement officers to make informed decisions in real-time and execute the narcotics interdiction process in a smooth and efficient manner for the officers and the broader community at hand.”

The 1064Defender Raman Analyzer is designed for ease-of-use and flexibility, allowing users to personalize the device to meet their individual needs. The analyzer is offered at a competitive price point, making it an affordable option for budget-restricted agencies that rely on narcotic interdiction specialists, border protection or law enforcement officials.

For more information on the Thermo Scientific 1064Defender Raman Analyzer, please visit thermofisher.com/1064defender